Trials / Completed
CompletedNCT01614899
A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
Randomized, Double-blind, Parallel- Group, Placebo-controlled, Confirmatory Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia <Phase 3>
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 457 (actual)
- Sponsor
- Sumitomo Pharma Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SM-13496 40mg | once daily orally |
| DRUG | SM-13496 80mg | once daily orally |
| DRUG | Placebo | once daily orally |
Timeline
- Start date
- 2012-07-02
- Primary completion
- 2014-11-17
- Completion
- 2014-11-17
- First posted
- 2012-06-08
- Last updated
- 2022-04-12
- Results posted
- 2018-10-19
Locations
4 sites across 4 countries: Japan, Malaysia, South Korea, Taiwan
Source: ClinicalTrials.gov record NCT01614899. Inclusion in this directory is not an endorsement.